GEP-NET (NEC)

Adrenal Gland/Adrenocortical Basket Trials (Multiple Types) Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI) Bladder/Urothelial (GU) Bone Metastases Brain and Central Nervous System (CNS) Breast Cervical (GYN) Colon/Rectal/Anal (GI) Endocrine Cancers Endocrine Neoplasia Esophageal (GI) Gastric/Stomach (GI) Gastrointestinal (GI) (Multiple Types) General Solid Tumors (Multiple Types) GenitoUrinary (GU) (Multiple Types) GEP-NET (NEC) GI Stromal Tumor (GIST) Gynecologic (GYN) (Multiple Types) Head and Neck Cancers Hepatocellular/Liver (GI) Hodgkins Lymphoma Insulinoma Kidney/Renal Cell Carcinoma (GU) Leukemias Lung Lymphomas Melanoma/Skin Cancers Mesothelioma Multiple Myeloma NeuroBlastoma NeuroEndocrine (NEC) (Multiple Types) NeuroEndocrine Carcinoma (NEC) Osteosarcoma Ovarian Ovarian/Primary Peritoneal (GYN) Pancreatic (GI) Paraganglioma (NEC) Penile (GU) Pheochromocytoma (NEC) Prostate (GU) Salivary Gland Sarcoma Synovial Carcinoma Testicular (GU) Thymoma Thyroid Unknown Primary Cancers Uterine (GYN) Vulvar (GYN)

Last Updated: Wed Jul 17 2024

Study Status

Enrolling

On Hold

Not Enrolling

Unknown

Treatment Undefined Stage

Lu177 Lutathera in Patients, Somatostatin (+) GEP-Neuroendocrine Tumors In Korea

NCT06155318

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Considering the rarity of GEP_NETs, it is quite difficult to collect a sufficient number of patients in order to investigate the accuracy, predictive and prognostic value of the currently available imaging technique in this scenario. Based on these considerations, the possibility to analyze PET images deriving from both PET/CT and PET/MRI scans of patients affected by GEP-NET is of fundamental relevance in order to provide answers to the currently unmet clinical needs.

NCT04919226

A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin

The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.

NCT03049189

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

🇺🇸

NCT06479811

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that target SSTRs can help shrink these types of tumors.